ParkinsonCanadaV1, Main, Exploration, bibRecord, 002F19

Neuroprotective actions of the ginseng extract G115 in two rodent models of Parkinson's disease

Identifieur interne : 002F19 ( Main/Exploration ); précédent : 002F18; suivant : 002F20

Neuroprotective actions of the ginseng extract G115 in two rodent models of Parkinson's disease

Auteurs : Jackalina Van Kampen [Canada] ; Harold Robertson [Canada] ; Theo Hagg [Canada] ; Robert Drobitch [Canada]

Source :

Experimental neurology : (Print) [ 0014-4886 ] ; 2003.

RBID : Pascal:04-0277518

Descripteurs français

Pascal (Inist)
- Parkinson maladie, Ginseng, Animal, Dégénérescence, Modèle, Mort cellulaire, Parkinsonisme, Potentiel action, Voie orale, Système nerveux pathologie, Neurotoxine, Souris, Métabolite, Rat, Traitement, Tyrosine 3-monooxygenase, Locus niger, Trouble fonctionnel, Rotation.

English descriptors

KwdEn :
- 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (antagonists & inhibitors), Action potential, Animal, Animals, Cell death, Degeneration, Dopamine Agents (toxicity), Dose-Response Relationship, Drug, Dysfunction, Female, Ginseng, Immunohistochemistry, Locomotion (physiology), Locus niger, Metabolite, Mice, Mice, Inbred C57BL, Models, Mouse, Nervous system diseases, Neuroprotective Agents, Neurotoxin, Oral administration, Panax (chemistry), Parkinson Disease, Secondary (pathology), Parkinson Disease, Secondary (physiopathology), Parkinson Disease, Secondary (prevention & control), Parkinson disease, Parkinsonism, Phytotherapy, Plant Extracts (therapeutic use), Pyridinium Compounds (toxicity), Rat, Rats, Rats, Sprague-Dawley, Rotation, Treatment, Tyrosine 3-monooxygenase.
MESH :
- chemical , antagonists & inhibitors : 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
- chemical , therapeutic use : Plant Extracts.
- chemical , toxicity : Dopamine Agents, Pyridinium Compounds.
- chemistry : Panax.
- pathology : Parkinson Disease, Secondary.
- physiology : Locomotion.
- physiopathology : Parkinson Disease, Secondary.
- prevention & control : Parkinson Disease, Secondary.
- Animals, Dose-Response Relationship, Drug, Female, Immunohistochemistry, Mice, Mice, Inbred C57BL, Neuroprotective Agents, Phytotherapy, Rats, Rats, Sprague-Dawley.

Abstract

The herbal remedy, ginseng, has recently been demonstrated to possess neurotrophic and neuroprotective properties, which may be useful in preventing various forms of neuronal cell loss including the nigrostriatal degeneration seen in Parkinson's disease (PD). In these studies, we examine the potential neuroprotective actions of the ginseng extract, G115, in two rodent models of PD. Animals received oral administration of G115 prior to and/or following exposure to the parkinsonism-inducing neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), in mice or its toxic metabolite, 1-methyl-4-phenylpyridinium (MPP⁺), in rats. Such treatment significantly and dramatically blocked tyrosine hydroxylase-positive cell loss in the substantia nigra and reduced the appearance of locomotor dysfunction. Thus, oral administration of ginseng appears to provide protection against neurotoxicity in rodent models of PD. Further examination of the neuroprotective actions of ginseng and its various elements may provide a potential means of slowing the progress of PD.

Affiliations:

Canada

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Neuroprotective actions of the ginseng extract G115 in two rodent models of Parkinson's disease</title>
<author><name sortKey="Van Kampen, Jackalina" sort="Van Kampen, Jackalina" uniqKey="Van Kampen J" first="Jackalina" last="Van Kampen">Jackalina Van Kampen</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Anatomy & Neurobiology, Dalhousie University, Tupper Medical Building</s1>
<s2>Halifax, Nova Scotia, B3H 4H7</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Halifax, Nova Scotia, B3H 4H7</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Robertson, Harold" sort="Robertson, Harold" uniqKey="Robertson H" first="Harold" last="Robertson">Harold Robertson</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Pharmacology, Dalhousie University, Tupper Medical Building</s1>
<s2>Halifax, Nova Scotia, B3H 4H7</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Halifax, Nova Scotia, B3H 4H7</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hagg, Theo" sort="Hagg, Theo" uniqKey="Hagg T" first="Theo" last="Hagg">Theo Hagg</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Anatomy & Neurobiology, Dalhousie University, Tupper Medical Building</s1>
<s2>Halifax, Nova Scotia, B3H 4H7</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Halifax, Nova Scotia, B3H 4H7</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Drobitch, Robert" sort="Drobitch, Robert" uniqKey="Drobitch R" first="Robert" last="Drobitch">Robert Drobitch</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>College of Pharmacy, Dalhousie University, Tupper Medical Building</s1>
<s2>Halifax, Nova Scotia, B3H 4H7</s2>
<s3>CAN</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Halifax, Nova Scotia, B3H 4H7</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">04-0277518</idno>
<date when="2003">2003</date>
<idno type="stanalyst">PASCAL 04-0277518 INIST</idno>
<idno type="RBID">Pascal:04-0277518</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000A04</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000319</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000938</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000938</idno>
<idno type="wicri:doubleKey">0014-4886:2003:Van Kampen J:neuroprotective:actions:of</idno>
<idno type="wicri:Area/Main/Merge">003324</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:14637121</idno>
<idno type="wicri:Area/PubMed/Corpus">001408</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001408</idno>
<idno type="wicri:Area/PubMed/Curation">001408</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001408</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001408</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001408</idno>
<idno type="wicri:Area/Ncbi/Merge">000372</idno>
<idno type="wicri:Area/Ncbi/Curation">000372</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000372</idno>
<idno type="wicri:doubleKey">0014-4886:2003:Van Kampen J:neuroprotective:actions:of</idno>
<idno type="wicri:Area/Main/Merge">003153</idno>
<idno type="wicri:Area/Main/Curation">002F19</idno>
<idno type="wicri:Area/Main/Exploration">002F19</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Neuroprotective actions of the ginseng extract G115 in two rodent models of Parkinson's disease</title>
<author><name sortKey="Van Kampen, Jackalina" sort="Van Kampen, Jackalina" uniqKey="Van Kampen J" first="Jackalina" last="Van Kampen">Jackalina Van Kampen</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Anatomy & Neurobiology, Dalhousie University, Tupper Medical Building</s1>
<s2>Halifax, Nova Scotia, B3H 4H7</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Halifax, Nova Scotia, B3H 4H7</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Robertson, Harold" sort="Robertson, Harold" uniqKey="Robertson H" first="Harold" last="Robertson">Harold Robertson</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Pharmacology, Dalhousie University, Tupper Medical Building</s1>
<s2>Halifax, Nova Scotia, B3H 4H7</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Halifax, Nova Scotia, B3H 4H7</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hagg, Theo" sort="Hagg, Theo" uniqKey="Hagg T" first="Theo" last="Hagg">Theo Hagg</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Anatomy & Neurobiology, Dalhousie University, Tupper Medical Building</s1>
<s2>Halifax, Nova Scotia, B3H 4H7</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Halifax, Nova Scotia, B3H 4H7</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Drobitch, Robert" sort="Drobitch, Robert" uniqKey="Drobitch R" first="Robert" last="Drobitch">Robert Drobitch</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>College of Pharmacy, Dalhousie University, Tupper Medical Building</s1>
<s2>Halifax, Nova Scotia, B3H 4H7</s2>
<s3>CAN</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Halifax, Nova Scotia, B3H 4H7</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Experimental neurology : (Print)</title>
<title level="j" type="abbreviated">Exp. neurol. : (Print)</title>
<idno type="ISSN">0014-4886</idno>
<imprint><date when="2003">2003</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Experimental neurology : (Print)</title>
<title level="j" type="abbreviated">Exp. neurol. : (Print)</title>
<idno type="ISSN">0014-4886</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (antagonists & inhibitors)</term>
<term>Action potential</term>
<term>Animal</term>
<term>Animals</term>
<term>Cell death</term>
<term>Degeneration</term>
<term>Dopamine Agents (toxicity)</term>
<term>Dose-Response Relationship, Drug</term>
<term>Dysfunction</term>
<term>Female</term>
<term>Ginseng</term>
<term>Immunohistochemistry</term>
<term>Locomotion (physiology)</term>
<term>Locus niger</term>
<term>Metabolite</term>
<term>Mice</term>
<term>Mice, Inbred C57BL</term>
<term>Models</term>
<term>Mouse</term>
<term>Nervous system diseases</term>
<term>Neuroprotective Agents</term>
<term>Neurotoxin</term>
<term>Oral administration</term>
<term>Panax (chemistry)</term>
<term>Parkinson Disease, Secondary (pathology)</term>
<term>Parkinson Disease, Secondary (physiopathology)</term>
<term>Parkinson Disease, Secondary (prevention & control)</term>
<term>Parkinson disease</term>
<term>Parkinsonism</term>
<term>Phytotherapy</term>
<term>Plant Extracts (therapeutic use)</term>
<term>Pyridinium Compounds (toxicity)</term>
<term>Rat</term>
<term>Rats</term>
<term>Rats, Sprague-Dawley</term>
<term>Rotation</term>
<term>Treatment</term>
<term>Tyrosine 3-monooxygenase</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Plant Extracts</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="toxicity" xml:lang="en"><term>Dopamine Agents</term>
<term>Pyridinium Compounds</term>
</keywords>
<keywords scheme="MESH" qualifier="chemistry" xml:lang="en"><term>Panax</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Parkinson Disease, Secondary</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Locomotion</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinson Disease, Secondary</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Parkinson Disease, Secondary</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Dose-Response Relationship, Drug</term>
<term>Female</term>
<term>Immunohistochemistry</term>
<term>Mice</term>
<term>Mice, Inbred C57BL</term>
<term>Neuroprotective Agents</term>
<term>Phytotherapy</term>
<term>Rats</term>
<term>Rats, Sprague-Dawley</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Ginseng</term>
<term>Animal</term>
<term>Dégénérescence</term>
<term>Modèle</term>
<term>Mort cellulaire</term>
<term>Parkinsonisme</term>
<term>Potentiel action</term>
<term>Voie orale</term>
<term>Système nerveux pathologie</term>
<term>Neurotoxine</term>
<term>Souris</term>
<term>Métabolite</term>
<term>Rat</term>
<term>Traitement</term>
<term>Tyrosine 3-monooxygenase</term>
<term>Locus niger</term>
<term>Trouble fonctionnel</term>
<term>Rotation</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The herbal remedy, ginseng, has recently been demonstrated to possess neurotrophic and neuroprotective properties, which may be useful in preventing various forms of neuronal cell loss including the nigrostriatal degeneration seen in Parkinson's disease (PD). In these studies, we examine the potential neuroprotective actions of the ginseng extract, G115, in two rodent models of PD. Animals received oral administration of G115 prior to and/or following exposure to the parkinsonism-inducing neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), in mice or its toxic metabolite, 1-methyl-4-phenylpyridinium (MPP<sup>+</sup>
), in rats. Such treatment significantly and dramatically blocked tyrosine hydroxylase-positive cell loss in the substantia nigra and reduced the appearance of locomotor dysfunction. Thus, oral administration of ginseng appears to provide protection against neurotoxicity in rodent models of PD. Further examination of the neuroprotective actions of ginseng and its various elements may provide a potential means of slowing the progress of PD.</div>
</front>
</TEI>
<affiliations><list><country><li>Canada</li>
</country>
</list>
<tree><country name="Canada"><noRegion><name sortKey="Van Kampen, Jackalina" sort="Van Kampen, Jackalina" uniqKey="Van Kampen J" first="Jackalina" last="Van Kampen">Jackalina Van Kampen</name>
</noRegion>
<name sortKey="Drobitch, Robert" sort="Drobitch, Robert" uniqKey="Drobitch R" first="Robert" last="Drobitch">Robert Drobitch</name>
<name sortKey="Hagg, Theo" sort="Hagg, Theo" uniqKey="Hagg T" first="Theo" last="Hagg">Theo Hagg</name>
<name sortKey="Robertson, Harold" sort="Robertson, Harold" uniqKey="Robertson H" first="Harold" last="Robertson">Harold Robertson</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002F19 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002F19 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:04-0277518
   |texte=   Neuroprotective actions of the ginseng extract G115 in two rodent models of Parkinson's disease
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

La maladie de Parkinson au Canada (serveur d'exploration)

Neuroprotective actions of the ginseng extract G115 in two rodent models of Parkinson's disease

Neuroprotective actions of the ginseng extract G115 in two rodent models of Parkinson's disease

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.